Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.38 |
| ▸ | IGF1R | P08069 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 4/20 | 0.35 |
| ▸ | VNN1 | O95497 | 3/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.31 |
| ▸ | CDK9 | P50750 | 4/20 | 0.31 |
| ▸ | CDK1 | P06493 | 3/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.31 |
| ▸ | CDK7 | P50613 | 3/20 | 0.31 |
| ▸ | CCNH | P51946 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2200708 | 0.87 | PLK1 (0.40) | PLK1IGF1RCDK2 | |
| SCHEMBL2200194 | 0.81 | VNN1 (0.36) | PLK1IGF1RCDK2VNN1 | |
| SCHEMBL2196305 | 0.81 | PLK1 (0.37) | PLK1IGF1RCDK2VNN1CDK1 | |
| SCHEMBL2196754 | 0.81 | PLK1 (0.39) | PLK1IGF1RCDK2 | |
| SCHEMBL3558617 | 0.81 | PLK1 (0.39) | PLK1IGF1RCDK2VNN1CCNT1 | |
| SCHEMBL3546850 | 0.80 | PLK1 (0.47) | PLK1IGF1RCDK2CDK1 | |
| SCHEMBL4257883 | 0.79 | ALDH1A1 (0.43) | PLK1IGF1RCDK2CDK1 | |
| SCHEMBL3550499 | 0.79 | PLK1 (0.39) | PLK1 | |
| SCHEMBL3546619 | 0.79 | PLK1 (0.39) | PLK1IGF1RCDK2VNN1CDK1 | |
| SCHEMBL3558801 | 0.79 | PLK1 (0.38) | PLK1IGF1RCDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | PLK1 1/4885IGF1R 812/4885CDK2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.